{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:13:27Z","timestamp":1767651207542},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00280-008-0797-4","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T03:21:36Z","timestamp":1217215296000},"page":"819-825","source":"Crossref","is-referenced-by-count":3,"title":["A multiple-center phase II study of biweekly oxaliplatin and tegafur\u2013uracil\/leucovorin for chemonaive patients with advanced gastric cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"Jen-Shi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Seng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Shen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ting","family":"Liau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Der","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Cheih","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruey-Ho","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,29]]},"reference":[{"key":"797_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"797_CR2","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2333::AID-CNCR15>3.0.CO;2-V","volume":"80","author":"SA Hundahl","year":"1997","unstructured":"Hundahl SA, Menck HR, Mansour EG, Winchester DP (1997) The National Cancer Data Base report on gastric carcinoma. Cancer 80:2333\u20132341","journal-title":"Cancer"},{"key":"797_CR3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163\u2013168","journal-title":"Ann Oncol"},{"key":"797_CR4","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","volume":"15","author":"SS W\u00f6hrer","year":"2004","unstructured":"W\u00f6hrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15:1585\u20131595","journal-title":"Ann Oncol"},{"key":"797_CR5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10120-005-0324-9","volume":"8","author":"A Ohtus","year":"2005","unstructured":"Ohtus A (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8:95\u2013102","journal-title":"Gastric Cancer"},{"issue":"Suppl 10","key":"797_CR6","first-page":"14","volume":"11","author":"Y Maehara","year":"1997","unstructured":"Maehara Y, Kakeji Y, Ohno S, Baba H, Sugimachi K (1997) Scientific basis for the combination of tegafur with uracil. Oncology (Huntington) 11(Suppl 10):14\u201318","journal-title":"Oncology (Huntington)"},{"key":"797_CR7","first-page":"2085","volume":"4","author":"DH Ho","year":"1998","unstructured":"Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J (1998) Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2\u2032-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4:2085\u20132088","journal-title":"Clin Cancer Res"},{"key":"797_CR8","first-page":"2417","volume":"20","author":"K Namatame","year":"1993","unstructured":"Namatame K, Sasaki E, Ko Y, Shimada K, Takahashi H, Nakano H, Midorikawa T, Makuuchi M, Kimura K, Kumada K (1993) A double-blind comparison of FUra plasma concentration by oral UFT vs continuous intravenous infusion (5-FU). Gan To Kagaku Ryoho 20:2417\u20132419 [in Japanese]","journal-title":"Gan To Kagaku Ryoho"},{"key":"797_CR9","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1200\/JCO.1998.16.8.2877","volume":"16","author":"H Takiuchi","year":"1998","unstructured":"Takiuchi H, Ajani JA (1998) Uracil\u2013tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 16:2877\u20132885","journal-title":"J Clin Oncol"},{"key":"797_CR10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/00001813-199710000-00009","volume":"8","author":"E Raymond","year":"1997","unstructured":"Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs 8:876\u2013885","journal-title":"Anticancer Drugs"},{"key":"797_CR11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1040-8428(01)00169-X","volume":"40","author":"Y Becouarn","year":"2001","unstructured":"Becouarn Y, Agostini C, Trufflandier N, Boulanger V (2001) Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 40:265\u2013272","journal-title":"Crit Rev Oncol Hematol"},{"key":"797_CR12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","volume":"7","author":"D Machover","year":"1996","unstructured":"Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N\u2019Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95\u201398","journal-title":"Ann Oncol"},{"key":"797_CR13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1008200825886","volume":"9","author":"E Diaz-Rubio","year":"1998","unstructured":"Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9:105\u2013108","journal-title":"Ann Oncol"},{"key":"797_CR14","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2005.17.749","volume":"23","author":"H Kelly","year":"2005","unstructured":"Kelly H, Goldberg RM (2005) Systemic chemotherapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23:4553\u20134560","journal-title":"J Clin Oncol"},{"key":"797_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0753-3322(97)81599-5","volume":"51","author":"M Eriguchi","year":"1997","unstructured":"Eriguchi M, Osada I, Fujii Y, Takeda Y, Yoshizaki I, Akiyama N, Yanagie H, Sekiguchi M, Kizu R, Matsushita H, Mathe G (1997) Pilot study for preoperative administration of 1-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother 51:217\u2013220","journal-title":"Biomed Pharmacother"},{"key":"797_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00001813-200008000-00010","volume":"11","author":"C Louvet","year":"2000","unstructured":"Louvet C, Coudray AM, Tournigand C, Prevost S, Raymond E, de Gramont A, Chazard M, Gespach C (2000) Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anticancer Drugs 11:579\u2013582","journal-title":"Anticancer Drugs"},{"key":"797_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00001813-200501000-00006","volume":"16","author":"JS Chen","year":"2005","unstructured":"Chen JS, Huang JS, Yang TS, Lin YC, Wang HM, Liau CT, Rau KM (2005) Phase I dosing-escalating study of oxaliplatin in combination with oral tegafur\u2013uracil and leucovorin in patients with advanced gastric cancer. Anticancer Drugs 16:47\u201351","journal-title":"Anticancer Drugs"},{"key":"797_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2001","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2001) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"797_CR19","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1200\/JCO.2002.02.021","volume":"20","author":"C Louvet","year":"2002","unstructured":"Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543\u20134548","journal-title":"J Clin Oncol"},{"key":"797_CR20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.2004.07.042","volume":"22","author":"SE Al-Batran","year":"2004","unstructured":"Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658\u2013663","journal-title":"J Clin Oncol"},{"key":"797_CR21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6601985","volume":"91","author":"Y Chao","year":"2004","unstructured":"Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK, Cheng AL (2004) Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 91:453\u2013458","journal-title":"Br J Cancer"},{"key":"797_CR22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/sj.bjc.6602697","volume":"93","author":"F Lordick","year":"2005","unstructured":"Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C (2005) Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93:190\u2013194","journal-title":"Br J Cancer"},{"key":"797_CR23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdj063","volume":"17","author":"A Jatoi","year":"2006","unstructured":"Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr, North Central Cancer Treatment Group (2006) Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:29\u201334","journal-title":"Ann Oncol"},{"key":"797_CR24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjc.6603046","volume":"94","author":"YH Park","year":"2006","unstructured":"Park YH, Kim BS, Ryoo BY, Yang SH (2006) A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 94:959\u2013963","journal-title":"Br J Cancer"},{"key":"797_CR25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000012099","volume":"58","author":"W Koizumi","year":"2000","unstructured":"Koizumi W, Kurihara M, Nakano S, Haegawa K (2000) Phase II study of S1, a novel derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191\u2013197","journal-title":"Oncology"},{"key":"797_CR26","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/sj.bjc.6602217","volume":"91","author":"J Feliu","year":"2004","unstructured":"Feliu J, Vicent JM, Garcia-Giron C, Constela M, Fonseca E, Aparicio J, Lomas M, Anton-Aparicio L, Dorta FJ, Gonzalez-Baron M, Oncopaz Cooperative Group Associated Hospitals (2004) Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer 91:1758\u20131762","journal-title":"Br J Cancer"},{"key":"797_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000087814","volume":"69","author":"G Rosati","year":"2005","unstructured":"Rosati G, Cordio S, Tucci A, Blanco G, Bordonaro R, Reggiardo G, Manzione L (2005) Phase II trial of oxaliplatin and tegafur\/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 69:122\u2013129","journal-title":"Oncology"},{"key":"797_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bjc.6602913","volume":"94","author":"J Bennouna","year":"2006","unstructured":"Bennouna J, Perrier H, Paillot B, Priou F, Jacob JH, Hebbar M, Bordenave S, Seitz JF, Cvitkovic F, Dorval E, Malek K, Tonelli D, Douillard JY (2006) A phase II study of oral uracil\/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 94:69\u201373","journal-title":"Br J Cancer"},{"key":"797_CR29","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"31","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 31:4991\u20134997","journal-title":"J Clin Oncol"},{"key":"797_CR30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346","journal-title":"N Engl J Med"},{"key":"797_CR31","first-page":"84","volume":"15","author":"P Sch\u00f6ffski","year":"2004","unstructured":"Sch\u00f6ffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15:84\u2013106","journal-title":"Anticancer Drugs"},{"key":"797_CR32","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/annonc\/mdl174","volume":"17","author":"W Ichikawa","year":"2006","unstructured":"Ichikawa W, Sasaki Y (2006) Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Ann Oncol 17:1665\u20131672","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0797-4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T04:25:36Z","timestamp":1554611136000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0797-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,29]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0797-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,29]]}}}